Revvity, Inc. operates in the rapidly growing markets of diagnostics and life sciences, providing essential tools and technologies for healthcare advancement. Amid a dynamic market landscape, it offers diversified products and solutions that cater to a broad spectrum of scientific research domains. The company’s reputation in innovation makes it a potential long-term asset in investors' portfolios.
The following table provides a breakdown of Revvity, Inc.'s fundamental scores, showcasing its strengths and areas for improvement.
| Category | Score | |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return On Equity | 3 | |
| Return On Assets | 3 | |
| Debt To Equity | 2 | |
| Price To Earnings | 1 | |
| Price To Book | 3 |
Below are the historical fundamental ratings of Revvity, Inc., indicating its financial trajectory.
| Date | Overall Score | DCF | ROE | ROA | Debt/Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-03-06 | 3 | 4 | 3 | 3 | 2 | 1 | 3 |
| Historical | 0 | 4 | 3 | 3 | 2 | 1 | 3 |
Analyst projections provide insight into the potential financial performance of Revvity, Inc.
| High | Low | Median | Consensus |
|---|---|---|---|
| $129 | $105 | $118 | $115.14 |
The table below indicates the current analyst recommendations for Revvity, Inc.
| Rating | Count | |
|---|---|---|
| Buy | 17 | |
| Hold | 12 |
Revvity, Inc. is positioned as a strong pick in the medical diagnostics and research sector due to its comprehensive portfolio and innovative solutions. While its price-to-earnings ratio indicates room for valuation improvement, strong cash flow and asset utilization scores suggest financial stability. Analyst consensus leans towards a 'Buy', reinforcing investor confidence. However, potential risks involve sector competition and operational cost challenges. Overall, Revvity presents a viable investment opportunity with promising growth potential.